Clostridioides difficile infection in inflammatory bowel disease: a clinical review

References

• Jorge L, Azula N, Smayevsky J, et al. Incidencia, características clínicas y evolución de la infección por Clostridioides difficile [Incidence, clinical characteristic and evolution of Clostridioides difficile infection]. Medicina-Buenos Aire. 2021;81(6):931–938. doi: 10.1038/s41579-020-0331-1
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibiotic-associated Pseudomembranous colitis. Gastroenterology. 1978;75(6):778–782. doi: 10.1016/0016-5085(78)90457-2
   PubMedGoogle Scholar
• Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298(10):531–534. doi: 10.1056/NEJM197803092981003
   PubMed Web of Science ®Google Scholar
• Borriello SP. The influence of the normal flora on clostridium difficile colonisation of the gut. Ann Med. 1990;22(1):61–67. doi: 10.3109/07853899009147244
   PubMed Web of Science ®Google Scholar
• Chandrasekaran R, Lacy DB. The role of toxins in clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723–750. doi: 10.1093/femsre/fux048
   PubMed Web of Science ®Google Scholar
• Martínez-Meléndez A, Cruz-López F, Morfin-Otero R, et al. An update on clostridioides difficile binary toxin. Toxins (Basel). 2022;14(5):305–317. doi: 10.3390/toxins14050305
   PubMed Web of Science ®Google Scholar
• Mounsey A, Lacy Smith K, Reddy VC, et al. Clostridioides difficile infection: update on management. Am Fam Physician. 2020;101(3):168–175. PMID: 32003951. doi: 10.1007/s11377-020-00435-w
   PubMed Web of Science ®Google Scholar
• Joshi NM, Marks IH, Crowson R, et al. Incidence and outcome of clostridium difficile infection in hospitalized patients with inflammatory bowel disease in the UK. J Crohns Colitis. 2017;11(1):70–76. doi: 10.1093/ecco-jcc/jjw117
   PubMed Web of Science ®Google Scholar
• Song JH, Kim YS. Recurrent clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16–24. doi: 10.5009/gnl18071
   PubMed Web of Science ®Google Scholar
• Pouch SM, Friedman-Moraco RJ. Prevention and treatment of clostridium difficile-associated diarrhea in solid organ transplant recipients. Infect Dis Clin N Am. 2018;32(3):733–748. doi: 10.1016/j.idc.2018.05.001
   PubMed Web of Science ®Google Scholar
• Capurso L, Koch M. Clostridium difficile infection and chronic inflammatory bowel disease. Recenti Prog Med. 2021;112(1):42–55. doi: 10.1701/3551.35256
   PubMedGoogle Scholar
• Finn E, Andersson FL, Madin-Warburton M. Burden of clostridioides difficile infection (CDI)-a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21(1):456. doi: 10.1186/s12879-021-06147-y
   PubMed Web of Science ®Google Scholar
• Guo CLT, Kwong TNY, Mak JWY, et al. Trends in incidence and clinical outcomes of clostridioides difficile infection, Hong Kong. Emerg Infect Dis. 2021;27(12):3036–3044. doi: 10.3201/eid2712.203769
   PubMed Web of Science ®Google Scholar
• Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of clostridioides difficile infection and outcomes. New Engl J Med. 2020;382(14):1320–1330. doi: 10.1056/NEJMoa1910215
   PubMed Web of Science ®Google Scholar
• Abernathy-Close L, Barron MR, George JM, et al. Intestinal inflammation and altered gut microbiota associated with inflammatory bowel disease render mice susceptible to clostridioides difficile colonization and infection. MBio. 2021;12(3):e0273320. doi: 10.1128/mBio.02733-20
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Sýkora J, Pomahačová R, Kreslová M, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24(25):2741–2763. doi: 10.3748/wjg.v24.i25.2741
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022;162(4):1147–1159. doi: 10.1053/j.gastro.2021.12.282
   PubMed Web of Science ®Google Scholar
• Carroll MW, Kuenzig ME, Mack DR, et al. The impact of inflammatory bowel disease in Canada 2018: children and adolescents with IBD. J Can Assoc Gastroenterol. 2019;2(1):S49–S67. doi: 10.1093/jcag/gwy056
   PubMedGoogle Scholar
• Singh H, Nugent Z, Yu BN, et al. Higher incidence of clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153(2):430–438. doi: 10.1053/j.gastro.2017.04.044
   PubMed Web of Science ®Google Scholar
• Chen XL, Deng J, Chen X, et al. High incidence and morbidity of clostridium difficile infection among hospitalized patients with inflammatory bowel disease: a prospective observational cohort study. J Dig Dis. 2019;20(9):460–466. doi: 10.1111/1751-2980.12798
   PubMed Web of Science ®Google Scholar
• Fletcher JR, Pike CM, Parsons RJ, et al. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. Nat Commun. 2021;12(1):462. doi: 10.1038/s41467-020-20746-4
   PubMed Web of Science ®Google Scholar
• Bassotti G, Fruganti A, Maconi G, et al. Clostridioides difficile infection in patients with inflammatory bowel disease may be favoured by the effects of proinflammatory cytokines on the enteroglial network. J Inflamm Res. 2021;14:7443–7453. doi: 10.2147/JIR.S328628
   PubMed Web of Science ®Google Scholar
• Barber GE, Hendler S, Okafor P, et al. Rising incidence of intestinal infections in inflammatory bowel disease: a nationwide analysis. Inflamm Bowel Dis. 2018;24(8):1849–1856. doi: 10.1093/ibd/izy086
   PubMed Web of Science ®Google Scholar
• Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. doi: 10.5009/gnl.2014.8.1.1
   PubMed Web of Science ®Google Scholar
• Rezapour M, Galoosian A, Liu B, et al. Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality. Eur J Gastroenterol Hepatol. 2018;30(9):1041–1046. doi: 10.1097/MEG.0000000000001185
   PubMed Web of Science ®Google Scholar
• Del Vecchio LE, Fiorani M, Tohumcu E, et al. Risk factors, diagnosis, and management of clostridioides difficile infection in patients with inflammatory bowel disease. Microorganisms. 2022;10(7):1315. doi: 10.3390/microorganisms10071315
   PubMed Web of Science ®Google Scholar
• LaMont JT, Trnka YM, Lamont JT. Therapeutic implications of clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980;1(8165):381–383. doi: 10.1016/s0140-6736(80)90939-3
   PubMed Web of Science ®Google Scholar
• Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980;1(8165):383–384. doi: 10.1016/s0140-6736(80)90940-x
   PubMed Web of Science ®Google Scholar
• Khanna S, Shin A, Kelly CP. Management of clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol H. 2017;15(2):166–174. doi: 10.1016/j.cgh.2016.10.024
   PubMed Web of Science ®Google Scholar
• Vitikainen K, Haapamäki J, Färkkilä M, et al. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study. Scand J Gastroenterol. 2018;53(8):947–951. doi: 10.1080/00365521.2018.1492012
   PubMed Web of Science ®Google Scholar
• Bolukcu S, Hakyemez IN, Gultepe BS, et al. Clostridium difficile infection: is there a change in the underlying factors? Inflammatory bowel disease and clostridium difficile. Saudi J Gastroenterol. 2019;25(6):384–389. doi: 10.4103/sjg.SJG_44_19
   PubMed Web of Science ®Google Scholar
• Tariq R, Law CCY, Khanna S, et al. The impact of clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2019;53(2):127–133. doi: 10.1097/MCG.0000000000000968
   PubMed Web of Science ®Google Scholar
• Viazis N, Pontas C, Karmiris K, et al. Prevalence of clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. Eur J Gastroenterol Hepatol. 2019;31(7):773–776. doi: 10.1097/MEG.0000000000001414
   PubMed Web of Science ®Google Scholar
• Zhang WT, Zhao HM, Luo YH, et al. Clostridium difficile infection and its susceptibility factors in children with inflammatory bowel disease. Chinese J Contemporary Pediatrics. 2021;23(7):718–723. doi: 10.7499/j.issn.1008-8830.2103129
   Google Scholar
• Chandrakumar A, Zohni H, El-Matary W. Clostridioides difficile infection in children with inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(11):1700–1706. doi: 10.1093/ibd/izz285
   PubMed Web of Science ®Google Scholar
• Lv T, Zheng L, Wu T, et al. Molecular characterization and antibiotic resistance of clostridioides difficile in patients with inflammatory bowel disease from two hospitals in China. J Glob Antimicrob Resist. 2022;30:252–258. doi: 10.1016/j.jgar.2022.06.017
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–1450. doi: 10.1111/j.1572-0241.2007.01780.x
   PubMed Web of Science ®Google Scholar
• Rodríguez C, Romero E, Garrido-Sanchez L, et al. Microbiota insights in clostridium difficile infection and inflammatory bowel disease. Gut Microbes. 2020;12(1):1725220. doi: 10.1080/19490976.2020.1725220
   PubMed Web of Science ®Google Scholar
• Shears P, Prtak L, Duckworth R. Hospital-based epidemiology: a strategy for ‘dealing with clostridium difficile’. J Hosp Infect. 2010;74(4):319–325. doi: 10.1016/j.jhin.2009.07.009
   PubMed Web of Science ®Google Scholar
• Saffouri G, Gupta A, Loftus EV Jr, et al. The incidence and outcomes from clostridium difficile infection in hospitalized adults with inflammatory bowel disease. Scand J Gastroenterol. 2017;52(11):1240–1247. doi: 10.1080/00365521.2017.1362466
   PubMed Web of Science ®Google Scholar
• Trifan A, Stanciu C, Stoica O, et al. Impact of clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol. 2014;20(33):11736–11742. doi: 10.1080/00365521.2017.1362466
   PubMed Web of Science ®Google Scholar
• Stecher B, Conway T, Cohen P. The roles of inflammation, nutrient availability and the commensal microbiota in enteric pathogen infection. Microbiol Spectr. 2015;3(3):10. doi: 10.1128/microbiolspec.MBP-0008-2014
   Google Scholar
• Li Y, Xu H, Xu T, et al. Case-control study of inflammatory bowel disease patients with and without clostridium difficile infection and poor outcomes in patients coinfected with C. difficile and cytomegalovirus. Dig Dis Sci. 2018;63(11):3074–3083. doi: 10.1007/s10620-018-5230-1
   PubMed Web of Science ®Google Scholar
• Lim HW, Schuster IP, Rajapakse R, et al. The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for clostridium difficile. Intestinal Res. 2019;17(2):244–252. doi: 10.5217/ir.2018.00101
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: treat registry. Clin Gastroenterol H. 2006;4(5):621–630. doi: 10.1016/j.cgh.2006.03.002
   PubMed Web of Science ®Google Scholar
• Zhang T, Lin QY, Fei JX, et al. Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease. Sci Rep. 2016;6(1):29791. doi: 10.1038/srep29791
   PubMedGoogle Scholar
• Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of clostridium difficile infection. Mol Immunol. 2015;63(2):193–202. doi: 10.1016/j.molimm.2014.09.005
   PubMed Web of Science ®Google Scholar
• Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019;13(1):27–38. doi: 10.1093/ecco-jcc/jjy143
   PubMed Web of Science ®Google Scholar
• Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Dig Liver Dis. 2014;46(12):1086–1092. doi: 10.1016/j.dld.2014.09.003
   PubMedGoogle Scholar
• Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the recidivism study. Am J Gastroenterol. 2016;111(8):1141–1146. doi: 10.1038/ajg.2016.187
   PubMed Web of Science ®Google Scholar
• Khanna S. Management of clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021;19(3):265–274. doi: 10.5217/ir.2020.00045
   PubMed Web of Science ®Google Scholar
• Sehgal K, Yadav D, Khanna S. The interplay of clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol. 2021;14:17562848211020285. doi: 10.1177/17562848211020285
   Web of Science ®Google Scholar
• Shoaei P, Shojaei H, Jalali M, et al. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. BMC Infect Dis. 2019;19(1):361. doi: 10.1186/s12879-019-3965-8
   PubMedGoogle Scholar
• Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018;18(3):296–307. doi: 10.1016/S1473-3099(17)30751-X
   PubMed Web of Science ®Google Scholar
• Adelman MW, Woodworth MH, Shaffer VO, et al. Critical care management of the patient with clostridioides difficile. Crit Care Med. 2021;49(1):127–139. doi: 10.1097/CCM.0000000000004739
   PubMed Web of Science ®Google Scholar
• Lei DK, Ollech JE, Andersen M, et al. Long-duration oral vancomycin to treat clostridioides difficile in patients with inflammatory bowel disease is associated with a low rate of recurrence. Am J Gastroenterol. 2019;114(12):1904–1908. doi: 10.14309/ajg.0000000000000460
   PubMed Web of Science ®Google Scholar
• Mikamo H, Tateda K, Yanagihara K, et al. Efficacy and safety of fidaxomicin for the treatment of clostridioides (clostridium) difficile infection in a randomized, double-blind, comparative phase III study in Japan. J Infect Chemother. 2018;24(9):744–752. doi: 10.1016/j.jiac.2018.05.010
   PubMed Web of Science ®Google Scholar
• Soriano MM, Liao S, Danziger LH. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of clostridium difficile infections. Expert Rev Anti Infect Ther. 2013;11(8):767–776. doi: 10.1586/14787210.2013.814767
   PubMed Web of Science ®Google Scholar
• D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with clostridium difficile infection. World J Gastroenterol. 2017;23(27):4986–5003. doi: 10.3748/wjg.v23.i27.4986
   PubMed Web of Science ®Google Scholar
• Ooijevaar RE, van Beurden YH, Terveer EM, et al. Update of treatment algorithms for clostridium difficile infection. Clin Microbiol Infect. 2018;24(5):452–462. doi: 10.1016/j.cmi.2017.12.022
   PubMed Web of Science ®Google Scholar
• Thorpe CM, Kane AV, Chang J, et al. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel clostridium difficile-targeting antibacterial, compared to vancomycin. PLOS ONE. 2018;13(8):e199810. doi: 10.1371/journal.pone.0199810
   Web of Science ®Google Scholar
• Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001. doi: 10.1016/S1473-3099(17)30325-0
   PubMed Web of Science ®Google Scholar
• Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889–1900. doi: 10.1053/j.gastro.2017.02.003
   PubMed Web of Science ®Google Scholar
• Rea MC, Sit CS, Clayton E, et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against clostridium difficile. Proc Natl Acad Sci, USA. 2010;107(20):9352–9357. doi: 10.1073/pnas.0913554107
   PubMed Web of Science ®Google Scholar
• Kołodziej M, Szajewska H. Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: a randomized clinical trial. Clin Microbiol Infect. 2019;25(6):699–704. doi: 10.1016/j.cmi.2018.08.017
   PubMed Web of Science ®Google Scholar
• Sivananthan K, Petersen AM. Review of saccharomyces boulardii as a treatment option in IBD. Immunopharm Immunot. 2018;40(6):465–475. doi: 10.1080/08923973.2018.1469143
   PubMed Web of Science ®Google Scholar
• Chen K, Zhu Y, Zhang Y, et al. A probiotic yeast-based immunotherapy against clostridioides difficile infection. Sci Transl Med. 2020;12(567):eaax4905. doi: 10.1126/scitranslmed.aax4905
   PubMed Web of Science ®Google Scholar
• Kang JD, Myers CJ, Harris SC, et al. Bile acid 7α-dehydroxylating gut bacteria secrete antibiotics that inhibit clostridium difficile: role of secondary bile acids. Cell Chem Biol. 2019;26(1):27–34. doi: 10.1016/j.chembiol.2018.10.003
   PubMed Web of Science ®Google Scholar
• Nagao-Kitamoto H, Leslie JL, Kitamoto S, et al. Interleukin-22-mediated host glycosylation prevents clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. Nat Med. 2020;26(4):608–617. doi: 10.1038/s41591-020-0764-0
   PubMed Web of Science ®Google Scholar
• Zhu LB, Zhang YC, Huang HH, et al. Prospects for clinical applications of butyrate-producing bacteria. World J Clin Pediatr. 2021;10(5):84–92. doi: 10.5409/wjcp.v10.i5.84
   PubMedGoogle Scholar
• Kaźmierczak-Siedlecka K, Daca A, Folwarski M, et al. The role of lactobacillus plantarum 299v in supporting treatment of selected diseases. Cent Eur J Immunol. 2020;45(4):488–493. doi: 10.5114/ceji.2020.101515
   PubMed Web of Science ®Google Scholar
• Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60(2):968–981. doi: 10.1128/AAC.01774-15
   PubMed Web of Science ®Google Scholar
• Jakubczyk D, Leszczyńska K, Górska S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)-a critical review. Nutrients. 2020;12(7):1973. doi: 10.3390/nu12071973
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994. doi: 10.1093/cid/ciy149
   PubMed Web of Science ®Google Scholar
• Guandalini S, Sansotta N. Probiotics in the treatment of inflammatory bowel disease. Adv Exp Med Biol. 2019;1125:101–107. doi: 10.1007/5584_2018_319
   PubMed Web of Science ®Google Scholar
• Ooijevaar RE, Terveer EM, Verspaget HW, et al. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2019;70(1):335–351. doi: 10.1146/annurev-med-111717-122956
   PubMedGoogle Scholar
• Dalal RS, Allegretti JR. Diagnosis and management of clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroen. 2021;37(4):336–343. doi: 10.1097/MOG.0000000000000739
   PubMed Web of Science ®Google Scholar
• Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62:596–602. doi: 10.1093/cid/civ938
   PubMed Web of Science ®Google Scholar
• Cheng YW, Phelps E, Ganapini V, et al. Fecal microbiota transplantation for the treatment of recurrent and severe clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am J Transplant. 2019;19(2):501–511. doi: 10.1111/ajt.15058
   PubMed Web of Science ®Google Scholar
• FDA approves first fecal microbiota product, Rebyota approved for the prevention of recurrence of clostridioides difficile infection in adults. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product
   Google Scholar
• Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30(1):51–58. doi: 10.1111/jgh.12727
   PubMed Web of Science ®Google Scholar
• Bauer CM, Zhang X, Long MD, et al. Characteristics of fecal microbiota transplantation use in inflammatory bowel disease cohort. Crohn’s Colitis 360. 2020;2(2):otaa024. doi: 10.1093/crocol/otaa024
   PubMedGoogle Scholar
• You JHS, Jiang X, Lee WH, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent clostridium difficile infection in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2020;35(3):1515–1523. doi: 10.1111/jgh.15002
   PubMedGoogle Scholar
• Ianiro G, Bibbò S, Porcari S, et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes. 2021;13(1):1994834. doi: 10.1080/19490976.2021.1994834
   PubMed Web of Science ®Google Scholar
• Porcari S, Baunwall SMD, Occhionero AS, et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Autoimmun. 2023;141:103036. doi: 10.1016/j.jaut.2023.103036
   PubMed Web of Science ®Google Scholar
• Quera R, Espinoza R, Estay C, et al. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent clostridium difficile infection. J Crohns Colitis. 2014;8(3):252–253. doi: 10.1016/j.crohns.2013.10.002
   PubMed Web of Science ®Google Scholar
• Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of feal microbiota transplantation for recurrent clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14(10):1433–1438. doi: 10.1016/j.cgh.2016.02.018
   PubMed Web of Science ®Google Scholar
• Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with clostridium difficile infection. Gastroenterology. 2017;152(4):799–811. doi: 10.1053/j.gastro.2016.11.010
   PubMed Web of Science ®Google Scholar
• Heuler J, Chandra H, Sun X. Mucosal Vaccination Strategies against Clostridioides difficile Infection. Vaccines. 2023;11(5):887. doi: 10.3390/vaccines11050887
   Web of Science ®Google Scholar
• Dose-confirmation, immunogenicity and safety study of the clostridium difficile vaccine Candidate VLA84 in healthy adults aged 50 years and older. Phase II study. Available from: https://www.wuxuwang.com/linchuangus/0bfa5794-a18d-11ea-82b4-00163e0eafb3?html=0×tamp=1691720337349
   Google Scholar
• Posteraro B, Pea F, Masucci L, et al. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? Expert Opin Biol Ther. 2018;18(4):469–476. doi: 10.1080/14712598.2018.1452908
   PubMed Web of Science ®Google Scholar
• Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis. 2018;67(5):649–656. doi: 10.1093/cid/ciy171
   PubMed Web of Science ®Google Scholar
• Bezlotoxumab (zinplava) for prevention of recurrent clostridium difficile infection. JAMA. 2017;318(7):659–660. doi: 10.1001/jama.2017.10092
   PubMed Web of Science ®Google Scholar
• Kelly CP, Wilcox MH, Glerup H, et al. Bezlotoxumab for clostridium difficile infection complicating inflammatory bowel disease. Gastroenterology. 2018;155(4):1270–1271. doi: 10.1053/j.gastro.2018.06.080
   PubMed Web of Science ®Google Scholar
• Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi: 10.1093/cid/ciab549
   PubMed Web of Science ®Google Scholar
• Clostridium difficile vaccine efficacy trial. Available from: https://www.wuxuwang.com/linchuangus/18025398-a18d-11ea-82b4-00163e0eafb3?html=0
   Google Scholar
• Study of a Candidate clostridium difficile toxoid vaccine in subjects at risk for C. difficile infection. Available from: https://www.wuxuwang.com/linchuangus/0597243b-a18d-11ea-82b4-00163e0eafb3?html=0
   Google Scholar
• Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med. 2022;386(3):220–229. doi: 10.1056/NEJMoa2106516
   PubMed Web of Science ®Google Scholar
• Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic clostridium difficile strain M3 for prevention of recurrent C difficile infection. JAMA. 2015;313(17):1719–1727. doi: 10.1001/jama.2015.3725
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu D, Sun X, et al. Development of an effective nontoxigenic clostridioides difficile–based oral vaccine against C. difficile infection. Microbiol Spectr. 2022;10(3):e0026322. doi: 10.1128/spectrum.00263-22
   PubMed Web of Science ®Google Scholar
• Hughes J, Aston C, Kelly ML, et al. Towards development of a non-toxigenic clostridioides difficile oral spore vaccine against toxigenic C. difficile. Pharmaceutics. 2022;14(5):1086. doi: 10.3390/pharmaceutics14051086
   PubMed Web of Science ®Google Scholar
• Gholam-Mostafaei FS, Yadegar A, Aghdaei HA, et al. Anti-TNF containing regimens may be associated with increased risk of clostridioides difficile infection in patients with underlying inflammatory bowel disease. Curr Res Transl Med. 2020;68(3):125–130. doi: 10.1016/j.retram.2020.03.002
   PubMed Web of Science ®Google Scholar
• Study on clinical outcomes and predictions of ustekinumab treatment in patients with Crohn’s disease. Available from: https://www.chictr.org.cn/showproj.html?proj=187721
   Google Scholar
• Green N, Miller T, Suskind D, et al. A review of dietary therapy for IBD and a vision for the future. Nutrients. 2019;11(5):947. doi: 10.3390/nu11050947
   PubMed Web of Science ®Google Scholar
• Levine A, Rhodes JM, Lindsay JO, et al. Dietary guidance from the international organization for the study of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(6):1381–1392. doi: 10.1016/j.cgh.2020.01.046
   PubMed Web of Science ®Google Scholar
• Owczarek D, Rodacki T, Domagała-Rodacka R, et al. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol. 2016;22(3):895–905. doi: 10.3748/wjg.v22.i3.895
   PubMed Web of Science ®Google Scholar
• Fritsch J, Garces L, Quintero MA, et al. Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19(6):1189–1199. doi: 10.1016/j.cgh.2020.05.026
   PubMed Web of Science ®Google Scholar
• Campmans-Kuijpers MJE, Dijkstra G. Food and food groups in inflammatory bowel disease (IBD): the design of the Groningen anti-inflammatory diet (GrAID). Nutrients. 2021;13(4):1067. doi: 10.3390/nu13041067
   PubMed Web of Science ®Google Scholar
• Chicco F, Magrì S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. Inflamm Bowel Dis. 2021;27(1):1–9. doi: 10.1093/ibd/izaa097
   PubMed Web of Science ®Google Scholar
• Oman Evans Ii M, Starley B, Galagan JC, et al. Tea and recurrent Clostridium difficile infection. Gastroenterol Res Pract. 2016;2016:1–5. doi: 10.1155/2016/4514687
   Web of Science ®Google Scholar
• Fitzpatrick JA, Melton SL, Yao CK, et al. Dietary management of adults with IBD - the emerging role of dietary therapy. Nat Rev Gastroenterol Hepatol. 2022;19(10):652–669. doi: 10.1038/s41575-022-00619-5
   PubMed Web of Science ®Google Scholar
• Wang S, Deng W, Li F, et al. Blockade of T helper 17 cell function ameliorates recurrent clostridioides difficile infection in mice. Acta Biochim Biophys Sin. 2021;53(10):1290–1299. doi: 10.1093/abbs/gmab107
   Google Scholar
• Aguirre AM, Sorg JA. Gut associated metabolites and their roles in clostridioides difficile pathogenesis. Gut Microbes. 2022;14(1):2094672. doi: 10.1080/19490976.2022.2094672
   PubMed Web of Science ®Google Scholar
• Azimirad M, Jo Y, Kim MS, et al. Alterations and prediction of functional profiles of gut microbiota after fecal microbiota transplantation for Iranian recurrent clostridioides difficile infection with underlying inflammatory bowel disease: a pilot study. J Inflamm Res. 2022;15:105–116. doi: 10.2147/JIR.S338212
   PubMed Web of Science ®Google Scholar
• Yanai H, Levine A, Hirsch A, et al. The Crohn’s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn’s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022;7(1):49–59. doi: 10.1016/S2468-1253(21)00299-5
   PubMed Web of Science ®Google Scholar